News
The company received notification of selection on March 30, 2024, and will participate in the American Society of Clinical Oncology (ASCO) annual meeting from May 31 to June 4, 2024.
more>>


Research

Our strategies focus on
(1)developing new chemical entities for tumor therapies
  -Like     LXP1788 

 

(2)searching new indications for carcinoma from medicines for chronic disease
  -Like 
LXP5268   LXP5101 


In future

In addition to pharmaceutical development,
we are also developingbiologic therapy .
We are expecting for increasing therapeutic effect of pharmaceutical through precise drug delivery.
We are looking forward to providing more efficiency of therapies and improving the quality of life.

了解更多